Ayala Pharmaceuticals

Ayala Pharmaceuticals is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations.

Industries

Pharmaceutical

Headquarters

Wilmington, United States

Stage

Post IPO Equity

Employees

11-50

Links

Org chart

Kenneth Berlin

President & CEO

Collapse

Dana Gelbaum

Chief Business Officer

Shmuel Tuvia

Chief Scientific Officer

Andres Gutierrez

Chief Medical Officer

Igor Gitelman

Interim Chief Financial Officer

David Caron

VP, CMC

Carmit Nadri-Shay

VP, Regulatory Affairs

Irit Klipper-Avni

VP, Human Resources

Teams

View all

Leadership Team

4 members

Board of Directors

7 members

CEO and Executive Team

1 members

Founding Team

0 members

Discover similar companies

Walgreens Boots Alliance

Deerfield, United States

Eli Lilly

Indianapolis, United States · Series E

Omnicell

Mountain View, United States

Alnylam Pharmaceuticals

Cambridge, United States · Post IPO Debt

Bristol-Myers Squibb

Lawrence Township, United States

AbbVie

North Chicago, United States · Series B

Prescient Healthcare Group

Jersey City, United States · Private Equity

Viatris

Pittsburgh, United States

Nano Hearing Aids

Phoenix, United States

Catalent

Franklin Township, United States · Venture

Rgenta Therapeutics

Woburn, United States · Series A

Cerevel Therapeutics

Boston, United States · Post IPO Debt

The Org
helps you hire
great candidates

It takes less than ten minutes to set up your company page.
It’s free to use - try it out today.